Further bolstering its potential application to Alzheimer’s disease (AD) therapy, compound 2 also functioned as an inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.